Osteomyelofibrosis Withdrawn Phase 2 Trials for Palifermin (DB00039)

Also known as: Chronic idiopathic myelofibrosis / Myelosis non-leukemic / Agnogenic myeloid metaplasia / Myelofibrosis / Myelosis-non-leukaemic / Myelosis non-leukaemic / Myelosis nonleukemic

IndicationStatusPhase
DBCOND0039445 (Osteomyelofibrosis)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00570999Palifermin After Haploidentical PBSCTTreatment